Impedimed Limited · ASX:IPD
Impedimed — Investor Presentation (October 2024)
18 slides from Impedimed's investor presentation, Oct 22, 2024
Slide 1: Investor Presentation
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 22 October 2024 Companies Announcements Office Australian Securities Exchange Investor Presentation ImpediMed Limited (ASX:IPD) releases the attached presentation to be delivered to
Slide 2: Q1 FY25 Results
Impedimed Limited Q1 FY25 Results October 2024 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. 1
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance,
Slide 4: Agenda
Agenda 1 Building a sustainable business – Strategy recap 2 Key metrics and Q1 FY25 results 3 Other Q1 highlights 4 SOZO® Digital Health Platform product roadmap update 5 Q2 FY25 outlook 3
Slide 5: Immediate strategy
Immediate strategy Execute to breakeven with a focus of sales, marketing and clinical execution in BCRL 12-Month Priorities Next 12 months: Execute towards break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-class customer Progress to break ev
Slide 6: Building a sustainable business
Building a sustainable business Momentum continues 1 New strategy changes implemented 2 Confidence in the business model • Forward sales indicators improving • Sales momentum increasing • Payor coverage increasing 3 Focus on cost control remains 4 Finalising product roadmap for future growth 5
Slide 7: New strategy changes implemented
New strategy changes implemented Refocus on sales growth • Completed market and customer segmentation analysis. • Refined marketing strategy and pricing model. • Headcount realigned to support sales with customer facing staff increasing by 15%. • Established structured sales processes and metrics: •
Slide 8: Q1/Q2 Initiatives driving awareness & lead generation
Q1/Q2 Initiatives driving awareness & lead generation Increasing conference attendance and media activity drives awareness and supports clinical adoption. • 15 national and regional conferences • 12 media placements with several more planned through Q2 • Two new study articles in highly respected jo
Slide 9: Key Metrics Improving
Key Metrics Improving Q1 FY25 Metrics Covered Lives1 Opportunity Pipeline Units 146.6M 585 5% vs Q4 FY24 34% increase vs Q4 FY24 3 additional payors providing coverage 1 new NCCN Center 16 States now at Critical Mass2 SOZO at 23/33 19 Private payors providing positive coverage3 New! - NAPBC Accredit
Slide 10: Forward sales indicators continue to improve
Forward sales indicators continue to improve U.S. SOZO Units Opportunity Pipeline1 Unit Opportunity up 100% Q1 FY25 Pipeline up 34% vs. Q4 FY24 1.Total Opportunity Pipeline represents validated leads for SOZO units in pipeline at end of quarter. 9
Slide 11: Core business revenue and TCV improving
Core business revenue and TCV improving Q1 FY25 Financial Highlights # SOZO units SOZO Core sold U.S. Business TCV 28 $4.8 million1 22% vs Q4 FY24 40% vs Q4 FY24 Total SOZO Core revenue Business ARR $2.7 million $11.6 million 7% vs Q4 FY24 5% vs Q4 FY24 1.Includes 3-year renewal of large multisystem
Slide 12: TCV – Momentum continues with record quarterly increase
TCV – Momentum continues with record quarterly increase A$ millions SOZO Core Business Quarterly Total Contract Value1 SOZO Annual Recurring Revenue2 • 6 networks contracted with 2-3 devices • ARR up 21% vs Q1 FY24 • Renewed a top 5 customer • Price of renewed contracts increased 19% on average 1.To
Slide 13: Revenue and Installed Base
Revenue and Installed Base ROW Installed Base Revenue Global Installed Base US Installed base A$ millions Units • Churn 3% annualized. Q1 FY25 revenue down 7% vs Q4 FY24 mainly due to: • U.S. installed base adjusted for inactive units • Lower ROW (timing of distributor inventory • 78 inactive or non
Slide 14: Cashflow
Cashflow Cashflow In thousands Q1 FY25 • Results largely in line with expectations. Board is comfortable with AUD Actual current cash position and continues to monitor closely. Receipts from customers 2,718 • FY25 budget phasing includes higher cash consumption in Q1 and Research & development (88)
Slide 15: Key Q1 highlights
Key Q1 highlights • National Accreditation Program for Breast Cancer Patient Tests (000s) Centers (NAPBC) Standards, released in October, included BIS for the first time in the Survivorship section • Installed Base growth driving • SOZO in 143/570 NAPBC centres increased Patient Testing • 71,000 Pat
Slide 16: SOZO Digital Health Platform product roadmap update
SOZO Digital Health Platform product roadmap update • Andrew Grant returned to Non-executive Director role after completing draft product roadmap for the SOZO Digital Health Platform following extensive workshop process and broad cross-functional input. Board now reviewing. • Rigorous business model
Slide 17: Outlook for Q2 FY25
Outlook for Q2 FY25 • Continued focus on Lymphoedema awareness activities to generate leads • Drive further improvement in sales and other key business metrics • Optimise contract renewal outcomes • Further expansion of private payor coverage • Continued cost focus with operating cash outflow expect
Slide 18: impedimed’
impedimed’